Cargando…

MRI grading for the prediction of prostate cancer aggressiveness

OBJECTIVES: T o evaluate the value of multiparametric MRI (mpMRI) for the prediction of prostate cancer (PCA) aggressiveness. METHODS: In this single center cohort study, consecutive patients with histologically confirmed PCA were retrospectively enrolled. Four different ISUP grade groups (1, 2, 3,...

Descripción completa

Detalles Bibliográficos
Autores principales: Boschheidgen, M., Schimmöller, L., Arsov, C., Ziayee, F., Morawitz, J., Valentin, B., Radke, K. L., Giessing, M., Esposito, I., Albers, P., Antoch, G., Ullrich, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921105/
https://www.ncbi.nlm.nih.gov/pubmed/34748064
http://dx.doi.org/10.1007/s00330-021-08332-8
_version_ 1784669265345904640
author Boschheidgen, M.
Schimmöller, L.
Arsov, C.
Ziayee, F.
Morawitz, J.
Valentin, B.
Radke, K. L.
Giessing, M.
Esposito, I.
Albers, P.
Antoch, G.
Ullrich, T.
author_facet Boschheidgen, M.
Schimmöller, L.
Arsov, C.
Ziayee, F.
Morawitz, J.
Valentin, B.
Radke, K. L.
Giessing, M.
Esposito, I.
Albers, P.
Antoch, G.
Ullrich, T.
author_sort Boschheidgen, M.
collection PubMed
description OBJECTIVES: T o evaluate the value of multiparametric MRI (mpMRI) for the prediction of prostate cancer (PCA) aggressiveness. METHODS: In this single center cohort study, consecutive patients with histologically confirmed PCA were retrospectively enrolled. Four different ISUP grade groups (1, 2, 3, 4–5) were defined and fifty patients per group were included. Several clinical (age, PSA, PSAD, percentage of PCA infiltration) and mpMRI parameters (ADC value, signal increase on high b-value images, diameter, extraprostatic extension [EPE], cross-zonal growth) were evaluated and correlated within the four groups. Based on combined descriptors, MRI grading groups (mG1–mG3) were defined to predict PCA aggressiveness. RESULTS: In total, 200 patients (mean age 68 years, median PSA value 8.1 ng/ml) were analyzed. Between the four groups, statistically significant differences could be shown for age, PSA, PSAD, and for MRI parameters cross-zonal growth, high b-value signal increase, EPE, and ADC (p < 0.01). All examined parameters revealed a significant correlation with the histopathologic biopsy ISUP grade groups (p < 0.01), except PCA diameter (p = 0.09). A mixed linear model demonstrated the strongest prediction of the respective ISUP grade group for the MRI grading system (p < 0.01) compared to single parameters. CONCLUSIONS: MpMRI yields relevant pre-biopsy information about PCA aggressiveness. A combination of quantitative and qualitative parameters (MRI grading groups) provided the best prediction of the biopsy ISUP grade group and may improve clinical pathway and treatment planning, adding useful information beyond PI-RADS assessment category. Due to the high prevalence of higher grade PCA in patients within mG3, an early re-biopsy seems indicated in cases of negative or post-biopsy low-grade PCA. KEY POINTS: • MpMRI yields relevant pre-biopsy information about prostate cancer aggressiveness. • MRI grading in addition to PI-RADS classification seems to be helpful for a size independent early prediction of clinically significant PCA. • MRI grading groups may help urologists in clinical pathway and treatment planning, especially when to consider an early re-biopsy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00330-021-08332-8.
format Online
Article
Text
id pubmed-8921105
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-89211052022-03-17 MRI grading for the prediction of prostate cancer aggressiveness Boschheidgen, M. Schimmöller, L. Arsov, C. Ziayee, F. Morawitz, J. Valentin, B. Radke, K. L. Giessing, M. Esposito, I. Albers, P. Antoch, G. Ullrich, T. Eur Radiol Urogenital OBJECTIVES: T o evaluate the value of multiparametric MRI (mpMRI) for the prediction of prostate cancer (PCA) aggressiveness. METHODS: In this single center cohort study, consecutive patients with histologically confirmed PCA were retrospectively enrolled. Four different ISUP grade groups (1, 2, 3, 4–5) were defined and fifty patients per group were included. Several clinical (age, PSA, PSAD, percentage of PCA infiltration) and mpMRI parameters (ADC value, signal increase on high b-value images, diameter, extraprostatic extension [EPE], cross-zonal growth) were evaluated and correlated within the four groups. Based on combined descriptors, MRI grading groups (mG1–mG3) were defined to predict PCA aggressiveness. RESULTS: In total, 200 patients (mean age 68 years, median PSA value 8.1 ng/ml) were analyzed. Between the four groups, statistically significant differences could be shown for age, PSA, PSAD, and for MRI parameters cross-zonal growth, high b-value signal increase, EPE, and ADC (p < 0.01). All examined parameters revealed a significant correlation with the histopathologic biopsy ISUP grade groups (p < 0.01), except PCA diameter (p = 0.09). A mixed linear model demonstrated the strongest prediction of the respective ISUP grade group for the MRI grading system (p < 0.01) compared to single parameters. CONCLUSIONS: MpMRI yields relevant pre-biopsy information about PCA aggressiveness. A combination of quantitative and qualitative parameters (MRI grading groups) provided the best prediction of the biopsy ISUP grade group and may improve clinical pathway and treatment planning, adding useful information beyond PI-RADS assessment category. Due to the high prevalence of higher grade PCA in patients within mG3, an early re-biopsy seems indicated in cases of negative or post-biopsy low-grade PCA. KEY POINTS: • MpMRI yields relevant pre-biopsy information about prostate cancer aggressiveness. • MRI grading in addition to PI-RADS classification seems to be helpful for a size independent early prediction of clinically significant PCA. • MRI grading groups may help urologists in clinical pathway and treatment planning, especially when to consider an early re-biopsy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00330-021-08332-8. Springer Berlin Heidelberg 2021-11-08 2022 /pmc/articles/PMC8921105/ /pubmed/34748064 http://dx.doi.org/10.1007/s00330-021-08332-8 Text en © The Author(s) 2021, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Urogenital
Boschheidgen, M.
Schimmöller, L.
Arsov, C.
Ziayee, F.
Morawitz, J.
Valentin, B.
Radke, K. L.
Giessing, M.
Esposito, I.
Albers, P.
Antoch, G.
Ullrich, T.
MRI grading for the prediction of prostate cancer aggressiveness
title MRI grading for the prediction of prostate cancer aggressiveness
title_full MRI grading for the prediction of prostate cancer aggressiveness
title_fullStr MRI grading for the prediction of prostate cancer aggressiveness
title_full_unstemmed MRI grading for the prediction of prostate cancer aggressiveness
title_short MRI grading for the prediction of prostate cancer aggressiveness
title_sort mri grading for the prediction of prostate cancer aggressiveness
topic Urogenital
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921105/
https://www.ncbi.nlm.nih.gov/pubmed/34748064
http://dx.doi.org/10.1007/s00330-021-08332-8
work_keys_str_mv AT boschheidgenm mrigradingforthepredictionofprostatecanceraggressiveness
AT schimmollerl mrigradingforthepredictionofprostatecanceraggressiveness
AT arsovc mrigradingforthepredictionofprostatecanceraggressiveness
AT ziayeef mrigradingforthepredictionofprostatecanceraggressiveness
AT morawitzj mrigradingforthepredictionofprostatecanceraggressiveness
AT valentinb mrigradingforthepredictionofprostatecanceraggressiveness
AT radkekl mrigradingforthepredictionofprostatecanceraggressiveness
AT giessingm mrigradingforthepredictionofprostatecanceraggressiveness
AT espositoi mrigradingforthepredictionofprostatecanceraggressiveness
AT albersp mrigradingforthepredictionofprostatecanceraggressiveness
AT antochg mrigradingforthepredictionofprostatecanceraggressiveness
AT ullricht mrigradingforthepredictionofprostatecanceraggressiveness